Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations: 2022-2025

Historic Income from Continuing Operations for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Income from Continuing Operations fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Income from Continuing Operations is -$54.9 million, which was down 9.03% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Income from Continuing Operations registered a high of -$24.9 million during Q2 2023, and its lowest value of -$111.3 million during Q4 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Income from Continuing Operations averaged around -$47.1 million, with its median value being -$42.6 million (2024).
  • In the last 5 years, Centessa Pharmaceuticals' Income from Continuing Operations skyrocketed by 61.51% in 2023 and then tumbled by 202.22% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$43.2 million in 2022, then grew by 14.68% to -$36.8 million in 2023, then plummeted by 202.22% to -$111.3 million in 2024, then decreased by 28.96% to -$54.9 million in 2025.
  • Its Income from Continuing Operations stands at -$54.9 million for Q3 2025, versus -$50.3 million for Q2 2025 and -$26.1 million for Q1 2025.